Press Release

March 31, 2021
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in non-invasive genetic testing and analysis of cfDNA, and Tesis Labs, a US multi-region lab services provider with labs in Colorado, Texas and Arizona, announced a strategic partnership in the field of prenatal genetic testing.

The collaboration will allow Tesis to broaden its portfolio of genetic testing offerings and participate in the fast growing screening market for over 4 million pregnancies in the United States. Tesis’s state-of-the-art and highly scalable genetics laboratory in Lafayette, Colorado can serve many regions of the U.S. including TexasArizona, and Colorado.

To read the full press release:


Apr 07, 2021

Tesis Labs Launching New Arizona Genetic Testing Facility – Opening November 2021

Tesis Labs, the leader in targeted genetic sequencing, announced its plans to expand to the Phoenix/Scottsdale area, offering targeted genetic sequencing services to healthcare providers in the western U.S. The new lab will be located in Scottsdale.

The Scottsdale lab will provide the additional capacity to handle the growth of the Company’s collaborative initiatives with large medical companies and research organizations looking to develop pharmaceuticals that impact the human genome, medical devices and large medical organizations focused on an improvement in the quality of care. The primary focus of the facility will be on high-complexity molecular and next-generation sequencing (NGS) testing to detect chronic and hereditary conditions such as cancer, heart disease, lung disease, diabetes, and Alzheimer’s. Also, the lab will offer Infectious Disease testing, including COVID-19, respiratory pathology, wound, and other molecular testing.

To read the full press release: